PDL grabs royalties, Depomed gets cash in diabetes drug deal

PDL BioPharma Inc. will buy the royalty rights to a portfolio of type 2 diabetes drugs and experimental therapies licensed by Depomed Inc...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.